According to the World Health Organization, cardiovascular disease (CVD) is the leading cause of death and disability in the world today. With more than 17.5 million deaths annually from CVD, finding effective treatment options is critical. Northwestern University Feinberg School of Medicine scientists are hard at work to find innovative new therapies to treat and prevent CVD.
Poor sleep may be a significant factor driving the differences in risk of cardiometabolic disease between African-Americans and European-Americans, according to a new study.
Mutations in the genes FOXC2 and GJC2 are associated with defects in venous valves, according to a new study published in the Journal of Experimental Medicine.
Fourth-year medical student Kyle Yoo has been selected as a Fogarty Global Health Fellow and will travel to Kerala, India to study the interplay between management practices and acute cardiac care.
Northwestern Medicine investigators identified key areas of agreement and disagreement between cardiovascular data collected from electronic health records and data gathered in a traditional cohort study.
The absence of obesity, diabetes and hypertension in middle age was associated with significantly fewer years lived with heart failure, according to a Northwestern Medicine study.
Coronary artery calcium — a sign of atherosclerosis — was found in more than one-third of women previously considered to be low-risk for heart disease, according to a Northwestern Medicine study.
In the first of its kind study, Northwestern Medicine scientists looked at the impact of this genetic condition on the risk of developing heart disease.
Burning kerosene and diesel fuel indoors for lighting, cooking and heating may increase the chance of developing fatal heart disease, according to recent research.
A minimally invasive procedure to repair aortic stenosis may be preferable to open-heart surgery when treating patients at intermediate risk of surgical mortality, according to recent research.
A clinical trial led by Northwestern Medicine scientist Mihai Gheorghiade, MD, opens the door for further investigation of a new drug to treat the more than one million patients in the United States hospitalized for heart failure every year.